Jpmorgan Chase & CO Rallybio Corp Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RLYB
# of Institutions
63Shares Held
32.1MCall Options Held
0Put Options Held
0-
Viking Global Investors LP4.19MShares$4.28 Million0.02% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.64MShares$3.71 Million1.68% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA3.63MShares$3.7 Million2.28% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY3.3MShares$3.37 Million5.39% of portfolio
-
Tpg Gp A, LLC Fort Worth, TX3.03MShares$3.09 Million0.1% of portfolio
About Rallybio Corp
- Ticker RLYB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,132,000
- Market Cap $32.8M
- Description
- Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...